Pharma Journalist 8769 posts 0 comments

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU)…
Read More...

BigHat Biosciences (“BigHat”), a biotechnology company with a machine learning (ML)-guided antibody discovery and development platform, announced a strategic collaboration with Eli…
Read More...

Cellino, a biotechnology company pioneering autonomous biomanufacturing for personalized regenerative medicine, announced its expansion into the Asia-Pacific region through a strategic…
Read More...

Boehringer Ingelheim and Cue Biopharma, Inc. announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a…
Read More...

Roche announced that the European Commission has approved Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed…
Read More...

Pfizer Inc. announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for…
Read More...

REVEAL GENOMICS and Ona Therapeutics announced a strategic collaboration aimed at accelerating the clinical development of ONA-255, a next-generation ADC designed to enhance the…
Read More...

Ironwood Pharmaceuticals, Inc., a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced…
Read More...

Bristol Myers Squibb announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class…
Read More...

Valneva SE, a specialty vaccine company announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose vaccine IXCHIQ for the…
Read More...